{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:22:56Z","timestamp":1791433376281,"version":"4.3.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.medj.2025.100960","type":"journal-article","created":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:15:59Z","timestamp":1767975359000},"page":"100960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Progressive multiple sclerosis: Six trials to watch"],"prefix":"10.1016","volume":"7","author":[{"given":"Maria A.","family":"Rocca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Preziosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2025.100960_bib1","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41573-022-00477-5","article-title":"Thinking outside the box: non-canonical targets in multiple sclerosis","volume":"21","author":"Bierhansl","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.medj.2025.100960_bib2","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","article-title":"Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion","volume":"269","author":"Filippi","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.medj.2025.100960_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ana.26913","article-title":"Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis","volume":"96","author":"Calabrese","year":"2024","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.medj.2025.100960_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100960_bib5","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2025.100960_bib6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaneurol.2022.5332","article-title":"Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review","volume":"80","author":"Dybowski","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.medj.2025.100960_bib7","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kramer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.medj.2025.100960_bib8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/iub.2798","article-title":"The CD40\/CD40 ligand dyad and its downstream effector molecule ISG54 in relating acute neuroinflammation with persistent, progressive demyelination","volume":"76","author":"Hazra","year":"2024","journal-title":"IUBMB Life"},{"key":"10.1016\/j.medj.2025.100960_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2025.e00558","article-title":"Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L)","volume":"22","author":"Conway","year":"2025","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.medj.2025.100960_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/brain\/awae362","article-title":"Current state and perspectives of CAR T cell therapy in central nervous system diseases","volume":"148","author":"Pfeffer","year":"2025","journal-title":"Brain"},{"key":"10.1016\/j.medj.2025.100960_bib11","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.medj.2025.100960_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106812","article-title":"CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation","volume":"104","author":"Ortuno-Sahagun","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.medj.2025.100960_bib13","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100960_bib14","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMoa2309439","article-title":"Inhibition of CD40L with Frexalimab in Multiple Sclerosis","volume":"390","author":"Vermersch","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2025.100960_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634025003873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T16:18:05Z","timestamp":1767975485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634025003873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2666634025003873"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2025.100960","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive multiple sclerosis: Six trials to watch","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2025.100960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100960"}}